Abstract Details

Title Individual Alpha Frequency for Diagnosis and Prognosis in Dementia

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 9-013

Background Dementia poses a global public health challenge, especially as populations age. Novel AD treatments necessitate precise diagnostics, but advanced techniques can be invasive and costly. EEG-derived IAF offers a non-invasive, cost-effective aid for diagnosis and prognosis in dementia.

Objective This study aimed to investigate the potential of the Individual Alpha Frequency (IAF) derived from electroencephalography (EEG) in stratifying patients with cognitive impairment based on the AT(N) classification system, differentiating clinical dementia subtypes, and predicting the conversion of mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia.

Design/Methods The study included 907 patients with cognitive impairment from a Memory Clinic. They underwent CSF lumbar puncture, clinical evaluation, neuropsychological assessment, imaging, and EEG. Patients were categorized by AT(N) criteria and clinical diagnoses. IAF was calculated from EEG data. Statistical analyses were conducted to assess correlations, compare IAF values among groups, and predict MCI conversion to AD dementia.

Results After stringent criteria, 375 patients remained. Correlation analysis found negligible associations between IAF and conventional clinical features. Within AT(N) groups, IAF was lower in A+ individuals and those with neurodegeneration markers. Combining A status with FDG-PET, A+/PET+ patients had lower IAF values compared to other combinations. IAF effectively distinguished AD and Lewy body dementia from other subtypes, including MCI. In the context of MCI conversion, IAF was significantly lower in converters (A+ MCIc) than stable MCI patients (A+ MCIs). A linear regression model showed IAF predicting time to conversion in A+ MCI patients (R2 = 0.38).

Conclusions This study underscores IAF's potential as a valuable asset in dementia diagnosis and prognosis. Its independence from traditional clinical markers, associations with amyloid status and neurodegeneration, and its ability to predict MCI conversion to AD dementia highlight its role in guiding timely and targeted interventions, particularly in the context of emerging disease-modifying therapies for AD.

Authors/Disclosures
Edoardo G. Spinelli, MD PRESENTER	Dr. Spinelli has nothing to disclose.
Giordano Cecchetti (San Raffaele Hospital)	Giordano Cecchetti has nothing to disclose.
Federica Agosta (San Raffaele Scientific Institute)	Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
Elisa Canu (Ospedale San Raffaele)	The institution of Elisa Canu has received research support from Italian Ministry of Health .
Silvia Basaia	Silvia Basaia has nothing to disclose.
Giulia Rugarli (San Raffaele Hospital)	No disclosure on file
Davide Curti	No disclosure on file
Federico Coraglia	No disclosure on file
Marco Cursi	No disclosure on file
Roberto Santangelo	No disclosure on file
Francesca Caso, MD (Universita' Vita Salute San Raffaele)	Dr. Caso has nothing to disclose.
Giovanna Fanelli	No disclosure on file
Giuseppe Magnani	Giuseppe Magnani has nothing to disclose.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit)	Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi;. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi- Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.